Literature DB >> 12271287

Drug interactions: Proteins, pumps, and P-450s.

Lori E Shapiro1, Neil H Shear.   

Abstract

UNLABELLED: The two major concerns in drug safety are adverse drug reactions and drug interactions. When multiple drug therapies are prescribed, drug interactions become an important consideration for patients and physicians. The life of a drug is reviewed with emphasis on absorption, distribution, metabolism, and excretion. Pharmacokinetic and pharmacodynamic mechanisms for drug interactions are reviewed. The contributions of P-glycoprotein, pharmacogenetic variation, and genetic polymorphisms to drug interactions are highlighted. Prediction of drug interactions is possible with knowledge of which agents are likely to cause alterations in drug metabolism. (J Am Acad Dermatol 2002;47:467-84.) LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should have an understanding of the life of a drug. This knowledge should help predict important potential drug interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271287     DOI: 10.1067/mjd.2002.126823

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  20 in total

Review 1.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.

Authors:  Abdo Haddad; Mellar Davis; Ruth Lagman
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.603

Review 3.  [Drug interactions in geriatric medicine].

Authors:  Angela Storka; Johannes Pleiner
Journal:  Wien Med Wochenschr       Date:  2009

4.  Skin and Psyche : Diversionary Symbiosis.

Authors:  Y K Sharma; S Sudarsanan; A Bhatnagar
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).

Authors:  U Schmitt; A Abou El-Ela; L J Guo; H Glavinas; P Krajcsi; J M Baron; C Tillmann; C Hiemke; P Langguth; S Härtter
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 6.  Functional evolution of the pregnane X receptor.

Authors:  Manisha Iyer; Erica J Reschly; Matthew D Krasowski
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-06       Impact factor: 4.481

7.  [Cost] effectiveness of withdrawal of fall-risk increasing drugs versus conservative treatment in older fallers: design of a multicenter randomized controlled trial (IMPROveFALL-study).

Authors:  Klaas A Hartholt; Nicole D A Boyé; Nathalie Van der Velde; Esther M M Van Lieshout; Suzanne Polinder; Oscar J De Vries; Albert J H Kerver; Gijsbertus Ziere; Milko M M Bruijninckx; Mark R De Vries; Francesco U S Mattace-Raso; André G Uitterlinden; Ed F Van Beeck; Paul Lips; Peter Patka; Tischa J M Van der Cammen
Journal:  BMC Geriatr       Date:  2011-08-21       Impact factor: 3.921

8.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

9.  Drug interactions in dermatology: what the dermatologist should know.

Authors:  Arijit Coondoo; Chandan Chattopadhyay
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

Review 10.  It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine.

Authors:  Anneka Sareen; Manisha Ramphul; Jayesh Mahendra Bhatt
Journal:  Breathe (Sheff)       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.